NCT02819271 is a Phase 1 clinical trial of CXL-1427 Ascending Dose in Heart Failure, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT02819271?

NCT02819271 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT02819271?

Interventions in NCT02819271: CXL-1427 Ascending Dose, Placebo, CXL-1427 Descending Dose.

What condition does NCT02819271 study?

NCT02819271 studies Heart Failure.

Is NCT02819271 still recruiting?

NCT02819271 is currently completed. Last updated 19 January 2017.

Last reviewed 2017-01-19 · How we verify

NCT02819271

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Completed Phase 1 Last updated 19 January 2017

What this trial tests

Phase 1 trial testing CXL-1427 Ascending Dose in Heart Failure in 80 participants. Completed in 1 April 2014.

Timeline

1 February 2014

Primary endpoint
1 April 2014

1 April 2014

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	1 February 2014
Primary completion	1 April 2014
Estimated completion	1 April 2014

Drugs / interventions tested

CXL-1427 Ascending Dose — full drug profile →
Placebo
CXL-1427 Descending Dose — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 45, any sex, with Heart Failure. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety measured by percentage of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 31 days
Tolerability measured by percentage of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 31 days

Sponsor's own description

This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Treatments targeting inotropy.
Maack C, Eschenhagen T, Hamdani N, Heinzel FR, et al · · 2019 · cited 151× · PMID 30295807 · DOI 10.1093/eurheartj/ehy600
Hurdles to Cardioprotection in the Critically Ill.
See Hoe LE, Bartnikowski N, Wells MA, Suen JY, et al · · 2019 · cited 3× · PMID 31387264 · DOI 10.3390/ijms20153823

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02819271 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 19 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02819271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing